Goldman Sachs 2025 U.S. Financial Services Conference December 9, 2025 1:00 PM ESTCompany ParticipantsNavid Mahmoodzadegan ...

Gov Hyacinth Iormem Alia of Benue State has said that he is determined to fix the broken Benue, some indigenes believed him ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...

The ASH oral presentation today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the September 13 ...

Discusses Strategic Portfolio Update and Leadership Transition December 8, 2025 9:00 AM ESTCompany ParticipantsJohn Nypaver - ...

IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).

Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread ...

With the right metrics, you can increase the return on both. by Jim Stengel, Cait Lamberton and Ken Favaro Over the past 20 years, performance marketing has become the dominant approach companies use ...